Story perspectives

AI-Powered Antibiotic Enterololin Targets Harmful E. Coli

10/7/2025

Summary

Researchers Unveil Antibiotic

Researchers at McMaster University and MIT discovered enterololin, a novel antibiotic for IBD, with mechanism of action (MOA) predicted by AI.
Enterololin is a narrow-spectrum drug targeting harmful E. coli strains, minimizing resistance risk.
AI cut MOA study duration from 2 years to 6 months and costs from $2 million to $60,000; Stoked Bio aims three-year human trials.

Summary

AI Revolutionizes Drug Discovery

Pauling. AI launched an automated drug discovery agent, speeding small-molecule testing and candidate selection.
AstraZeneca signed a $555 million deal with Algen Biotechnologies to deploy its AI platform for immunology discovery, focusing on CRISPR.
Insilico Medicine introduced LEGION, generating over 123 billion molecules to boost discovery and intellectual-property protection, and identified 34,000 NLRP3 scaffolds to deter rivals.

History

Historical Context

In 1928, Alexander Fleming discovered penicillin, the first antibiotic, while observing its antibacterial properties in a contaminated culture at St. Mary's Hospital, London. This serendipitous finding led to the development of mass production techniques during World War II, significantly reducing infection-related deaths. The 1945 Nobel Prize in Physiology or Medicine recognized Fleming, Howard Florey, and Ernst Chain for their groundbreaking work in antibiotic treatment.

1 of 3

Researchers Unveil Antibiotic

Researchers at McMaster University and MIT discovered enterololin, a novel antibiotic for IBD, with mechanism of action (MOA) predicted by AI.
Enterololin is a narrow-spectrum drug targeting harmful E. coli strains, minimizing resistance risk.
AI cut MOA study duration from 2 years to 6 months and costs from $2 million to $60,000; Stoked Bio aims three-year human trials.

1 / 3